Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study

Abstract Purpose Immunotherapy with atezolizumab and bevacizumab is the current first-line standard of care for unresectable hepatocellular carcinoma (HCC). This study aimed to evaluate the safety and efficacy profile of atezolizumab-bevacizumab in the Indian population, as there are limited studies...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Merin Babu, Ashok Sebastian Komaranchath, Arun Valsan, Arun R. Warrier, Rakesh MP, Wesley M. Jose, Nikhil K. Haridas, Sumi Soman, Manjima P. Nair, Shine Sadasivan, Abhinav Menon, Mohammed Thabrez, Keechilat Pavithran
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2025-07-01
Edice:	BMC Cancer
Témata:	atezolizumab bevacizumab hepatocellular carcinoma real world immune checkpoint inhibitors
On-line přístup:	https://doi.org/10.1186/s12885-025-14400-9
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!